Skip to content
Armando Hasudungan

Overview

Urinary incontinence is defined by the International Continence Society as the objective demonstration of involuntary leakage of urine. It is a common and distressing clinical condition that severely impacts physical health, psychological well-being, and overall quality of life. The condition is broadly caused by a disruption in the coordinated lower urinary tract mechanisms responsible for urine storage and voiding, involving the detrusor muscle of the bladder, the bladder neck, the urethral sphincters, and their complex central and autonomic neural innervation.

Epidemiologically, urinary incontinence is a global health issue with a strong female predominance. It affects approximately 30–50% of women at some point in their lives, with peak incidence occurring during menopause and advancing age.

In men, the overall prevalence is lower (~5–15%), rising significantly in older males where it is most commonly secondary to benign prostatic hyperplasia (BPH) or post-prostatectomy sphincter dysfunction.

Due to embarrassment and social stigma, the condition remains significantly underreported, with fewer than half of affected individuals seeking medical evaluation.

Definition

Stress Urinary Incontinence (SUI): Involuntary leakage of urine occurring on effort, physical exertion, sneezing, coughing, or laughing due to hypermobility of the bladder neck or intrinsic sphincter deficiency.

Urge Urinary Incontinence (UUI): Involuntary leakage of urine accompanied or immediately preceded by a sudden, compelling desire to void that is difficult to defer.

Overactive Bladder (OAB): A symptom syndrome characterized by urinary urgency, usually accompanied by frequency and nocturia, with or without urge urinary incontinence, in the absence of proven infection or metabolic disease.

Overflow Incontinence: Involuntary leakage of urine occurring when intravesical pressure exceeds maximal urethral pressure due to chronic urinary retention and bladder overdistension.

Post-Void Residual (PVR) Volume: The volume of urine remaining in the bladder immediately following completion of voluntary micturition, measured via ultrasound or catheterization.

Urinary Incontinence Overview

What to notice

Detailed image description

Source
Credit
Rights
Article figure
Figure 1 of 1 — 100%

Anatomy & Physiology

Physiology of Micturition

Classification

Mixed Urinary Incontinence is extremely common in clinical practice. Always determine which component (stress vs. urge) is most bothersome to the patient, as initial treatment should target the primary symptom.

Risk Factors

Female-Specific Risk Factors

Male-Specific Risk Factors

Reversible Triggers for incontinence (“DIAPPERS” Mnemonic)

Always rule out and correct reversible, transient causes of urinary incontinence (such as UTIs, severe constipation, or diuretic timing) before undertaking extensive urodynamic investigations or invasive procedures.

Pathophysiology

Stress Incontinence Pathophysiology

Urge Incontinence Pathophysiology

Overflow Incontinence Pathophysiology

Clinical Manifestation

Stress Urinary Incontinence

Urge Urinary Incontinence / Overactive Bladder

Overflow Incontinence

Adult-onset nocturnal enuresis (wetting the bed at night) in a male patient with a history of lower urinary tract symptoms is a major red flag for Overflow Incontinence secondary to severe urinary retention.

Prolapse with coexist with stress incontinenece in over 50% of cases, and an enquiry about symptoms is essential.

Get access to premium images

Sign up

Investigations

Initial Bedside Evaluation

Specialised Investigations

Treatment

Management follows a stepwise approach, starting with non-invasive lifestyle and conservative interventions before escalating to pharmacotherapy or surgery.

1. General Conservative Measures (For ALL Types)

2. Management of Stress Urinary Incontinence (SUI)

3. Management of Urge Urinary Incontinence (UUI / OAB)

4. Management of Overflow Incontinence

Mirabegron (Beta-3 agonist) is the drug of choice for Overactive Bladder in elderly patients because it avoids the central anticholinergic burden and cognitive decline associated with traditional drugs like Oxybutynin.

Complications & Prognosis

Complications

Prognosis

References

  1. Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence: 6th International Consultation on Incontinence. Tokyo: Clinical Consultation Location Ltd; 2017.
  2. Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017;3:17042. doi:10.1038/nrdp.2017.42
  3. Kobashi KC, Albo ME, Dmochowski RR, et al. Surgical treatment of female stress urinary incontinence: AUA/SUFU guideline. J Urol. 2017;198(4):875-883. doi:10.1016/j.juro.2017.04.087